Completed PHASE3 INTERVENTIONAL NCT00129857

Dexanabinol in Severe Traumatic Brain Injury

Efficacy and Safety Evaluation of a Single Intravenous Dose of Dexanabinol in Patients Suffering From Severe Traumatic Brain Injury

Sponsor: Pharmos

Conditions Traumatic Brain Injury

Interventions Dexanabinol

Updated 5 times since 2017 Last updated: May 4, 2006 Started: Jan 31, 2001 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00129857, this PHASE3 trial focuses on Traumatic Brain Injury and remains completed. Sponsored by Pharmos, it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pharmos

Data source: Pharmos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.